Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 vs investigator’s choice in HR+/HER2- advanced breast cancer
CTR20232807Phase 3Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in breast cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Oct 2023; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232807.